Lilly Adds Dual-Acting Insomnia Compound With Acquisition Of Hypnion
Deal will add the Phase II compound HY10275 to Lilly’s existing insomnia candidate pruvanserin.
Deal will add the Phase II compound HY10275 to Lilly’s existing insomnia candidate pruvanserin.